Biosimilar Billing Proposal For Medicare Contrary To Statute, Sen. Hatch Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Strong words from the Senate Finance Committee chairman suggest the confirmation process for Andrew Slavitt to be CMS administrator could become a showdown over biosimilar billing codes should the agency stick with its plan to put all biosimilars referencing the same innovator product into the same code.